Cargando…
Likely a matter of time for Amyloid-β immunotherapy
Amyloid-β peptide (Aβ) deposition in the brain is an early feature of Alzheimers’ disease. In a phase II clinical trial recently published in The New England Journal of Medicine, Mintun and colleagues report on the safety and efficacy of an antibody targeting Aβ peptide in amyloid plaques for the tr...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8985757/ https://www.ncbi.nlm.nih.gov/pubmed/35602205 http://dx.doi.org/10.1038/s43856-021-00010-6 |